neurology

Digital

pharmaphorum podcast Episode 236, Tarek Samad, Lundbeck

An AI supercomputer and discovering next-gen brain disorder ...

Tarek Samad, Lundbeck’s senior vice president and head of research, discusses AI – specifically, Lundbeck’s agreement with the DCAI to operate Gefion.

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

News

FDA clears trial of 'vectorised' ALS antibody from VectorY

VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.

News

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

News

An older man holds his head in pain while lights flash

Stroke data breathes life back into Bayer's asundexian

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

uniQure poleaxed as FDA blocks Huntington's therapy

uniQure has revealed that the FDA has said it is not prepared to review its Huntington's gene therapy in what seems to be a change in policy.

An AI supercomputer and discovering next-gen brain disorder ...

Q4 Clinical trials round-up: October to December 2025

FDA clears trial of 'vectorised' ALS antibody from VectorY

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

Stroke data breathes life back into Bayer's asundexian

uniQure poleaxed as FDA blocks Huntington's therapy

J&J jumps on the MFN pricing train

How to meet your physicians where they are online

neurology

Editor's Picks